Welcome to our dedicated page for Charming Medical news (Ticker: MCTA), a resource for investors and traders seeking the latest updates and insights on Charming Medical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Charming Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Charming Medical's position in the market.
Charming Medical (Nasdaq: MCTA) announced full exercise of the underwriters' 15% over-allotment option, adding 240,000 Class A ordinary shares at the public offering price of $4.00 per share. The over-allotment generated gross proceeds of $0.96 million, bringing aggregate gross proceeds from the initial public offering to approximately $7.36 million before underwriting discounts and offering expenses.
The company's Class A ordinary shares began trading on the Nasdaq Capital Market on October 21, 2025. The company said it intends to use net proceeds for business expansion, strategic investments and acquisitions, research and development, and general working capital.
Charming Medical (Nasdaq: MCTA) closed its initial public offering on October 22, 2025, selling 1,600,000 Class A ordinary shares at a public offering price of $4.00 per share for gross proceeds of $6.4 million before underwriting discounts and offering expenses.
The Class A ordinary shares began trading on the Nasdaq Capital Market under the symbol MCTA on October 21, 2025. The company granted underwriters a 45-day over-allotment option to buy up to an additional 240,000 shares (15%), which would raise gross proceeds to approximately $7.36 million if fully exercised.
The company intends to use net proceeds for business and geographic expansion, potential strategic investments and acquisitions, research and development, and general working capital and corporate purposes. The offering was conducted on a firm commitment basis and was declared effective by the SEC on September 30, 2025.
Charming Medical (Nasdaq: MCTA) priced an initial public offering of 1,600,000 Class A ordinary shares at $4.00 per share, with expected gross proceeds of approximately $6.4 million. Shares are expected to begin trading on the Nasdaq Capital Market on October 21, 2025, and the offering is expected to close on or about October 22, 2025, subject to customary closing conditions.
The underwriters have a 45‑day over‑allotment option for an additional 240,000 shares (15%), which would raise gross proceeds to about $7.36 million. Net proceeds are intended for geographic expansion, strategic investments, R&D, and working capital.
FAQ
What is the current stock price of Charming Medical (MCTA)?
What is the market cap of Charming Medical (MCTA)?
